Analyst Opinion Summary: Aquinox Pharmaceuticals, Inc. (AQXP), Innovative Industrial Properties, Inc. (IIPR)

Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) tinted gains of +3.28% (+0.08 points) to US$2.52. The volume of 0.17 Million shares climbed down over an trading activity of 92.04 Million shares. EPS ratio determined by looking at last 12 month figures is -1.93. Over the same time span, the stock marked US$16.9 as its best level and the lowest price reached was US$1.96. The corporation has a market cap of US$59.35 Million.

Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP)’s earnings per share has been growing at a -12 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at -48.8 percent while most common profitability ratio return on investment (ROI) was 0 percent. The company’s institutional ownership is monitored at 77.6 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 0 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 2 think it is Hold. Recently, analysts have updated the overall rating to 3. 0 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

Innovative Industrial Properties, Inc. (NYSE:IIPR) is worth US$624.64 Million and has recently fallen -0.92% to US$65.96. The latest exchange of 0.21 Million shares is below its average trading activity of 254.55 Million shares. The day began at US$0 but the price moved to US$0 at one point during the trading and finally capitulating to a session high of US$0. The stock tapped a 52-week high of US$68.21 while the mean 12-month price target for the shares is US$59.83.

Currently, the stock carries a price to earnings ratio of 118.85, a price to book ratio of 3.19, and a price to sales ratio of 50.78. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown 0%. With an institutional ownership near 33.2%, it carries an earnings per share ratio of 0.56.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 3 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 0 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.